Australia's most trusted
source of pharma news
Friday, 17 May 2024
Posted 29 April 2024 AM
After 650 days trudging through the PBAC and PBS processes, a new trial has convinced the Federal Government to subsidise the first additional medicine for at-risk breast cancer patients in more than 15 years.
Eli Lilly's CDK 4&6 inhibitor Verzenio will be listed on the PBS from 1 May to treat Australians with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), at high risk of recurrence after early breast cancer.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.